A crossover, add-on trial of talampanel in patients with refractory partial seizures.
The authors report a double-blind, placebo-controlled, crossover study of talampanel in 49 patients with refractory partial seizures. Three doses of talampanel were investigated based on differences in patients' concomitant antiepileptic drug usage. Talampanel showed efficacy in reducing seizure frequency (p = 0.001) with a median seizure reduction of 21%. Eighty percent of patients had fewer seizures on talampanel than on placebo. Dizziness (52%) and ataxia (26%) were the only significant adverse events.
Chappell
A S
AS
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. aschappell@lilly.com
Sander
J W
JW
Brodie
M J
MJ
Chadwick
D
D
Lledo
A
A
Zhang
D
D
Bjerke
J
J
Kiesler
G M
GM
Arroyo
S
S
D000328:Adult; D000927:Anticonvulsants / Q000008:administration & dosage; D001569:Benzodiazepines / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D002220:Carbamazepine / Q000008:administration & dosage; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000188:drug therapy*; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014635:Valproic Acid / Q000008:administration & dosage
D000927:Anticonvulsants; D018691:Excitatory Amino Acid Antagonists; D001569:Benzodiazepines; D002220:Carbamazepine; D014635:Valproic Acid; C085266:talampanel